SAN DIEGO--(BUSINESS WIRE)--
AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, announces that management will hold a business update conference call on Monday, May 15, 2017 beginning at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
|
Live Call: |
U.S. | 877-866-5534 | ||
| International | 346-406-0930 | |||
| Passcode | 20313217 | |||
| Live Webcast: | ||||
|
The webcast replay will be available approximately 2 hours |
||||
|
after completion of the call and will be archived for 30 days. |
||||
| Replay: | U.S. | 855-859-2056 | ||
| International | 404-537-3406 | |||
| Passcode | 20313217 | |||
|
The replay will be available for 48 hours starting approximately |
||||
|
2 hours after completion of the call. |
||||
About AmpliPhi Biosciences
AmpliPhi Biosciences Corporation is a biotechnology company pioneering the development and commercialization of therapies for antibiotic-resistant infections using bacteriophage-based technology. In May 2017, AmpliPhi announced a new strategic emphasis on developing precisely targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. AmpliPhi has reported results from two Phase 1 clinical trials of AB-SA01, one for the treatment of S. aureus in chronic rhinosinusitis patients (safety and preliminary efficacy) and one to evaluate the safety of AB-SA01 when administered topically to the intact skin of healthy adults.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170511005278/en/
